CA2222984A1 - Novel rat - Google Patents

Abstract

The invention provides RAT polypeptides and DNA (RNA) encoding RAT polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing RAT polypeptide for the protection against infection, particularly bacterial infections.

Description

, . . .

Novel RAT

FIELD OF Tl~E INVENTION

S This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the amidotransferase family, hereinafter referred to as "RAT".

BACKGROUND OF THE INVENTION

It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics. The Staphylococci make up a medically important genera of microbes. They are known to produce two types of disease, invasive and toxigenic.
15 Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues. S. aureus is the second leading cause of bacteremia in cancer patients. Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result 20 from the actions of exotoxins as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome.
Aminoacyl-tRNA synthetases (aaRS) catalyse the ligation of amino acids to their cognate tRNA species in all cellular organisms. In general, each of the twenty amino acids that are incorporated into growing polypeptide chains has a corresponding aaRS. However, it is 25 now well documented that this is not universally true and that glutaminyl-tRNA synthetase (QRS) activity is absent in all Gram-positive prokaryotes examined, in some Gram-negative prokaryotes and in the plastids of some, and possibly all, eukaryotes.
Despite the absence of glutaminyl-tRNA synthetase activity, cells are clearly able to produce the Gln-tRNAGln required for accurate protein synthesis. The mechanism by which 30 this is achieved involves the formation of Glu-tRNAGln as an intermediate that is produced by the mi~minoacylation of tRNAGln by glutamyl-tRNA synthetase (ERS). The 'correct' end -GM500 l 2P

product, Gln-tRNAGln, is formed from Glu-tRNAGln by transfer of an amine group to the ligated glutamate residue. This reaction is catalysed by a tRNA- and Mg2+/ATP-dependent amidotransferase. (RNA-dependent AmidoTransferase - RAT). Inhibition of this potentially ubiquitous reaction in Gram-positive org~ni~m~7 and some Gram-negative organisms, would 5 effectively lead to Gln-tRNAGln starvation and the consequent cessation of bacterial protein synthesis.
Although the amidotransferase reaction has been documented in a number of organi~m~, very little in-depth experimental work has been performed in any one biological system it appears that the reaction may be widely spread occurrence in nature and has been 10 documented in the following organisms: Bacillus magaterium, Bacillus subtilis, Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptomyces coelicolor, Enterococcus faecalis, Rhizobium meliloti and in several archaebacteria, cyanobacteria, mitochondria and chloroplasts. The process is absent from some Gram-negative eubacteria (e.g. Escherichia coli) and from the cytosol of eukaryotes where the reaction is rendered unnecessary due to the 15 existence of QRS activity.
The enzyme activity is broadly similar to that of other aminotransferases and toglutamine synthase (GS) although in the latter case the preferred amide donor is NH4+ as opposed to glutamine. The putative physiological substrate for RAT is glutamineas this is the preferred substrate for most amidotransferase reactions in metabolism and has proved to be the 20 best in vitro substrate for RATs in Bacillus subtilis, Chlamydomonas reinhardtii and Lactobacillus bulgaricus although asparagine and NH4+ can substitute to some extent. (In Bacillus subtilis, km for Gln=lOuM, Asn=100-200uM and NH4Cl 25mM). Evidence suggests [l] that, like GS, the glutamate molecule undergoes phosphorylation at the ~-carbon as an intermediate in the amidation reaction. The total requirements for RAT activity are Mg2+, 25 ATP, Glu-tRNAGln, and an amide donor (glutamine).
The unique feature concerning novel RAT of the invention which separates it fromother amidotransferases is its specific dependence upon Glu-tRNAGln for activity. (RAT will not catalyse transamidation of Glu-tRNAGln treated with ribonuclease nor will it catalyse transamidation of Glu-tRNAGlu; additionally, it has been demonstrated that RAT from 30 Chlamydomonas will form a tight complex with Glu-tRNAGln in the presence of ATP and absence of glutamine). RAT must therefore possess protein structural elements that necessarily GM500 l 2P

recognise glutamine and ATP (as do e.g. GS and QRS) but also very specifically, and perhaps uniquely, must recognise Glu-tRNAGln.
Two publications discuss sensitivity to inhibitors [2,3]. Results differ in each case and the reasons for this are unclear. Although the source of enzyme differs (B.subtilis and 5 Chlamydomonas reinhardtii) the apparently conflicting data may result from subtle differences in conditions. In the case of RAT from B.subtilis, the enzyme is sensitive to the general GS
inhibitor MSOX (methionine sulfoximine) but is not inhibited by the glutamine amidotransferase inhibitor DON (6-diazo-5-oxo-L-norleucine). RAT from C. reinhardtii is reported to be fully sensitive to DON.
Attempts to purify RAT from both B.subtilis [3] and Chlamydomonas reinhardtii [2]
have been made. The product from B.subtilis was only partially purified, was unstable and could not retain activity ovemight even at -70~C and was (unlike GS) heat labile. The purification from C. reinhardtii was more successful. The protein has a subunit molecular mass of ~63kDa and is a homodimer; the protein has been purified to, or near to, homogeneity. No 15 protein or DNA sequence data appears to be available despite publication of this purification procedure in 1990.
Clearly, there is a need for factors that may be used to screen compounds for antibiotic activity and which factors may also be used to determine their roles in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such 20 factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.

SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides that have been identified as novel RAT polypeptides by homology between the amino acid sequence detemmined by sequencing the RAT polypeptide.
It is a further object of the invention to provide polynucleotides that encode RAT
polypeptides, particularly polynucleotides that encode the polypeptide herein designated RAT.
In a particularly preferred embodiment of this aspect of the invention the polynucleotide comprises a region encoding RAT polypeptides.

-In another particularly preferred embodiment of the invention there is a novel RAT
protein from Staphylococcus aureus comprising the amino acid sequence determined by sequencing the RAT protein, or a variant thereof.
In accordance with this aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Stap1lylococcus aureus WCUH 29 strain contained in NCIMB Deposit No. 40771.
In accordance with this aspect of the invention there are provided isolated nucleic acid molecules encoding RAT, particularly Staphylococcus aureus RAT, including mRNAs, cDNAs, genomic DNAs. Further embodiments of this aspect of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of this aspect of the invention are naturally occurring allelic variants of RAT and polypeptides encoded thereby.
In accordance with this aspect of the invention there are provided novel polypeptides of Staphylococcus aureus referred to herein as RAT as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
Among the particularly preferred embodiments of this aspect of the invention are variants of RAT polypeptide encoded by naturally occurring alleles of the gene.
In a preferred embodiment of this aspect of the invention there are provided methods for producing the aforementioned polypeptides.
In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.
In accordance with certain preferred embodiments of this aspect of the invention, there are provided products, compositions and methods for (i) assessing expression, (ii) treating disease, for example, disease, such as, infections of the upper respiratory tract (e.g., otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestin~l (e.g., secretory diarrhoea, splenic absces, retroperitoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, , keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and perinephric absces, toxic shock syndrome), skin (e.g., impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis) bone and joint (e.g., septic arthritis, osteomyelitis), (iii) assaying genetic variation, (iv) and administering a polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a Staphylococcus aureus bacteria.
In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to polynucleotide sequences, particularly under stringent conditions.
In certain preferred embodiments of this aspect of the invention there are provided antibodies against RAT polypeptides.
In accordance with another aspect of the invention, there are provided RAT agonists and antagonists each of which are also preferably bacteriostatic or bacteriocidal.
In a further aspect of the invention there are provided compositions comprising a RAT
15 polynucleotide or a RAT polypeptide for administration to a cell or to a multicellular organism.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily ~ lClll to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings depict certain embodiments of the invention. They are illustrative only and do not limit the invention otherwise disclosed herein.
Figure I shows Staphylococcus aureus ERS gene sequence.
Figure 2 shows Stapl~)lococcus aureus ERS protein sequence.
GLOSSARY
The following definitions are provided to facilitate understanding of certain terms used frequently herein.
"Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
In the art, "identity" also means the degree of sequence relatedness bet~,veen polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of 5 such sequences. "Identity" and "similarity" can be readily calculated by known methods (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing~ fonnatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, 10 G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity and similarity between two sequences, both terms are well known to skilled artisans (Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Prinzer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988). Methods commonly employed to determine identity or similarity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J. Applied Math., 48:1073 (1988).
Preferred methods to determine identity are designed to give the largest match bet~,veen the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1). 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., J. Molec. Biol. 215: 403-410 (1990)). The BLAST X program is publicly available from NCBI and other sources (BLASTMaMual, Altschul, S., et al., NCBI
NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990)).
"Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single-and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-5 stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
The strands in such regions may be from the same molecule or from different molecules. The 10 regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein.
15 Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of 20 polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)" embraces short polynucleotides often referred to as oligonucleotide(s).
"Polypeptide(s)" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide(s)" refers to both 25 short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids. "Polypeptide(s)" include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques which are well known to the art. Such modifications are well described in basic texts 30 and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be -present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECUL~R PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993) and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSL~lTIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990) and Rattan et al., Protein Synthesis. Posttranslational Modifications and Aging, Ann. N.Y. Acad. Sci. 663:
48-62 (1992). Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
"Variant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A
typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

DESCRIPTION OF THE INVENTION
The invention relates to novel RAT polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a novel RAT gene homologous to the those of Staphylococcus aw~eus obtained from the RAT
protein sequence. The invention relates especially to RAT having the nucleotide and amino acid 15 sequences determined by analysis of the RAT protein, and to the RAT nucleotide sequences of the DNA in NCIMB Deposit No. 40771 and amino acid sequences encoded thereby. The invention provides RAT protein prepared from cell Iysates of S.aureus WCUH29. The Iysates are shown to have a specific RAT activity of between about 0.1 - 0.3nmoles/min/mg or RAT activity. The examples provided herein indicate methods for determining RAT activity. Highly purified 20 preparations have a specific activity of about 25nmoles/min/mg. Material of this purity was run on native SDS polyacrilamide electrophoresis gels and shows a principal species consistent with a molecular weight 110kD. Electrophoresis on reducing SDS Page show two species of approximately 54kD and 55kD. This suggests the molecule exists as a heterodimer.Heterotrimeric and monomeric forms are also provided by the invention. Polypeptides of the 25 invention include the 54kD, 55kD and the 110kD heterodimer, among other forms.
Techniques are available to evaluate temporal gene expression in bacteria, particularly as it applies to viability under laboratory and host infection conditions. A number of methods can be used to identify genes which are essential to survival per se, or essential to the establishment and/or maintenance of an infection. Identification of expression of a sequence 30 by one of these methods yields additional information about its function and assists in the . CA 02222984 1998-02-06 -selection of such sequence for further development as a screening target. Briefly, these approaches include for example;
1) Signature Tagged Mutagenesis (STM) This technique is described by Hensel et al., Science 269: 400-403(1995), the contents of which is incorporated by reference for background purposes. Signature tagged mutagenesis identifies genes necessary for the establishment/maintenance of infection in a given infection model.
The basis of the technique is the random mutagenesis of target organism by various means (e.g., transposons) such that unique DNA sequence tags are inserted in close proximity to the site of mutation. The tags from a mixed population of bacterial mutants and bacteria recovered from an infected hosts are detected by amplification, radiolabeling and hybridization analysis. Mutants attenuated in virulence are revealed by absence of the tag from the pool of bacteria recovered from infected hosts.
In Staphylococcus aureus, because the transposon system is less well developed, a more efficient way of creating the tagged mutants is to use the insertion-duplication mutagenesis technique as described by Morrison et al., J. Bacteriol. 159:870 (1984) the contents of which is incorporated by reference for background purposes.

2) In Vivo Expression Technology (IVET) This technique is described by Camilli et al., Proc. Nat'l. Acad. Sci. USA. 91:2634-2638 (1994) and Mahan et al., Infectious Agents and Diseases 2:263-268 (1994), the contents of each of which is incorporated by reference for background purposes. IVET identifies genes up-regulated during infection when compared to laboratory cultivation, implying an important role in infection. Sequences identified by this technique are implied to have a significant role in infection establishment/maintenance.
In this technique random chromosomal fragments of target organism are cloned upstream of a promoter-less reporter gene in a plasmid vector. The pool is introduced into a host and at various times after infection bacteria may be recovered and assessed for the presence of reporter gene expression. The chromosomal fragment carried upstream of an expressed reporter gene should carry a promoter or portion of a gene normally upregulated during infection. Sequencing upstream of the reporter gene allows identification of the up regulated gene.

;
-3) Differential display This technique is described by Chuang et al., J. Bacteriol. 175:2026-2036 (1993), the contents of which is incorporated by reference for background purposes. This method identifies those genes which are expressed in an organism by identifying mRNA present using 5 randomly-primed RT-PCR. By comparing pre-infection and post infection profiles, genes up and down regulated during infection can be identified and the RT-PCR product sequenced and matched to library sequences.

4) Generation of conditional lethal mutants by transposon mutagenesis.
This technique, described by de Lorenzo, V. et al., Gene 123: 17-24 (1993);
I 0 Neuwald, A. F. et al., Gene 125: 69-73(1993); and Takiff, H. E. et al., J. Bacteriol.
174:1544-1553(1992), the contents of which is incorporatedbyreference forbackground purposes, identifies genes whose expression are essential for cell viability.
In this technique transposons carrying controllable promoters, which provide transcription outward from the transposon in one or both directions, are generated. Random 15 insertion of these transposons into target organisms and subsequent isolation of insertion mutants in the presence of inducer of promoter activity ensures that insertions which separate promoter from coding region of a gene whose expression is essential for cell viability will be recovered. Subsequent replica plating in the absence of inducer identifies such insertions, since they fail to survive. Sequencing of the fl~nking regions of the transposon allows identification 20 of site of insertion and identification of the gene disrupted. Close monitoring of the changes in cellular processes/morphology during growth in the absence of inducer yields information on likely function of the gene. Such monitoring could include flow cytometry (cell division, Iysis, redox potential, DNA replication), incorporation of radiochemically labeled precursors into DNA, RNA, protein, lipid, peptidoglycan, monitoring reporter enzyme gene fusions which 25 respond to known cellular stresses.

5) Generation of conditional lethal mutants by chemical mutagenesis.
This technique is described by Beckwith, J., Methods in En~ymolo~y 204:
3- 18(1991), the contents of which are incorporated herein by reference for background purposes. In this technique random chemical mutagenesis of target organism, growth at 30 temperature other than physiological temperature (permissive temperature) and subsequent replica plating and growth at different temperature (e.g., 42~C to identify ts, 25~C to identify ' CA 02222984 1998-02-06 -cs) are used to identify those isolates which now fail to grow (conditional mutants). As above close monitoring of the changes upon growth at the non-permissive temperature yields information on the function of the mutated gene. Complementation of conditional lethal mutation by library from target organism and sequencing of complementing gene allows 5 matching with library sequences.
Each of these techniques may have advantages or disadvantage depending on the particular application. The skilled artisan would choose the approach that is the most relevant with the particular end use in mind. For example, some genes might be recognised as essential for infection but in reality are only necessary for the initiation of infection and so their products 10 would represent relatively unattractive targets for antibacterials developed to cure established and chronic infections.

6) RT-PCR
Bacterial messenger RNA, preferably that of S~aphylococcus aureus, is isolated from bacterial infected tissue, e.g., 48 hour murine lung infections, and the amount of each mRNA
15 species assessed by reverse transcription of the RNA sample primed with random hexanucleotides followed by PCR with gene specific primer pairs. The determination of the presence and amount of a particular mRNA species by quantification of the resultant PCR
product provides information on the bacterial genes which are transcribed in the infected tissue. Analysis of gene transcription can be carried out at different times of infection to gain 20 a detailed knowledge of gene regulation in bacterial pathogenesis allowing for a clearer understanding of which gene products represent targets for screens for novel antibacterials.
Because of the gene specific nature of the PCR primers employed it should be understood that the bacterial mRNA preparation need not be free of m~mm~ n RNA. This allows the investigator to carry out a simple and quick RNA preparation from infected tissue to obtain 25 bacterial mRNA species which are very short lived in the bacterium (in the order of 2 minute halflives). Optimally the bacterial mRNA is prepared from infected murine lung tissue by mechanical disruption in the presence of TRIzole (GIBCO-BRL) for very short periods of time, subsequent processing according to the manufacturers of TRIzole reagent and DNAase treatment to remove contaminating DNA. Preferably the process is optimized by finding those 30 conditions which give a maximum amount of bacterial 16S ribosomal RNA, preferably that of Staphylococcus au~ eus, as detected by probing Northerns with a suitably labeled sequence ' CA 02222984 1998-02-06 -specific oligonucleotide probe. Typically, a 5' dye labelled primer is used in each PCR primer pair in a PCR reaction which is terminated optimally between 8 and 25 cycles. The PCR
products are separated on 6% polyacrylamide gels with detection and quantification using GeneScanner (manufactured by ABI).
Use of the of these technologies when applied to the sequences of the invention enables identification of bacterial proteins expressed during infection, inhibitors of which would have utility in anti-bacterial therapy. This invention provides that RAT is an essential gene.
Deposited materials A deposit containing a Staphylococcus aureus WCUH 29 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (NCIMB), 23 St. Machar Drive, Aberdeen AB2 lRY, Scotland on 11 September 1995 and assigned NCIMB Deposit No. 40771.
The Staphylococcus aureus strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."
The deposited material is a strain that contains the full length RAT DNA, referred to as "NCIMB 40771" upon deposit.
The sequence of the polynucleotides contained in the deposited material, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.
The deposit has been made under the terms of the Budapest Treaty on the International 20 Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposit is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. 112.
A license may be required to make, use or sell the deposited materials, and no such 25 license is hereby granted.

- ' CA 02222984 1998-02-06 Polypeptides The polypeptides of the invention include the RAT polypeptide (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of RAT, and also those which have at least 70% identity to the RAT polypeptide or the relevant portion, preferably at least ~0% identity to the RAT polypeptide, and more preferably at least 90% similarity (more preferably at least 90% identity) to the RAT polypeptide and still more preferably at least 95% similarity (still more preferably at least 95% identity) to the RAT
polypeptide and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.
Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides. Variants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.
A fra~ment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides. As with RAT polypeptides fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.
Preferred fragments include, for example, truncation polypeptides having a portion of the RAT amino acid sequence, or of variants thereof, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a Staphylococcus aureus, are also preferred. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Also preferred are biologically active fragments which are those fragments that mediate activities of RAT, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human.
Polynucleotides Another aspect of the invention relates to isolated polynucleotides which encode the RAT
polypeptide having the amino acid sequence determined by sequencing the RAT protein, a specific example of which is set forth in Example 3 and includes the 54kD, 55kD, and an l lOkD
heterodimer. Using the information provided herein, such polynucleotide sequence, a 10 polynucleotide of the invention encoding RAT polypeptide may be obtained using standard cloning and screening, such as those for cloning and sequencing chromosomal DNA fragments from Staphylococcus aureus WCUH 29 cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as that which encodes the RAT polypeptide having the amino acid sequence determined by sequencing 15 the RAT protein, typically a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 in E.coli or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence, such as such as one derived from the amino acid sequence determined by sequencing the RAT protein. Clones carrying DNA
identical to that of the probe can then be distinguished using stringent conditions. By 20 sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., MOLECULAR CLONING, A LABORATORYMA~UAL, 25 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spnng Harbor, New York (1989). (see Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Illustrative of the invention, a polynucleotide such as that which encodes the RAT
polypeptide having the amino acid sequence determined by sequencing the RAT protein. RAT
protein isolated from Staph. aureus run on a non-denaturing PAGE gel has a molecular weight of 30 about l lOkD. RAT protein isolated from Stap1l. aureus run on a denaturing PAGE gel has two molecular weight species one of about 54kD and the other about 55kD.

RAT of the invention is beleived structurally related to other proteins of the amidotransferase family, as shown by the results of RAT enzymatic activity.
Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a 5 fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence. The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional lO coding sequence which encode additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE
vector (Qiagen, Inc.) and described in Gentz et al., Proc. Natl. Acad. Sci., USA 86: 821-824 (1989), or an HA tag (Wilson et al., Cell 37. 767 (1984)). Polynucleotides of the invention also 15 include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.
In accordance with the foregoing, the term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides which include a sequence encoding a polypeptide of the invention, particularly bactenal, and more particularly the Staphylococcus aureus RAT having the 20 amino acid sequence determined by sequencing the RAT protein. The term encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.
The invention further relates to variants of the herein above described polynucleotides 25 which encode for variants of the polypeptide having the deduced amino acid sequences.
Further particularly preferred embodiments are polynucleotides encoding RAT variants, which have the amino acid sequence of RAT polypeptide determined by sequencing the RAT
protein, in which several, a few, S to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent 30 substitutions, additions and deletions, which do not alter the properties and activities of RAT.

Further preferred embodiments of the invention are polynucleotides that are at least 70%
identical over their entire length to a polynucleotide encoding RAT polypeptide having the RAT
amino acid sequence, and polynucleotides which are complementary to such polynucleotides.
Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 5 80% identical over their entire length to a polynucleotide encoding RAT polypeptide of the Staphylococcus aureus DNA of the deposited strain and polynucleotides complementary thereto.
In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among l O those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.
Preferred embodiments in this respect, moreover, are polynucleotides which encode polypeptides which retain substantially the same biological function or activity as the mature RAT polypeptide.
The invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.
20 An example of stringent hybridization conditions is overnight incubation at 42~C in a solution comprising: 50% formamide, 5xSSC (150mM NaC1, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65~C. Hybridization and wash conditions are well known and exemplified in Sambrook, el al., 25 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter l l therein, the disclosure of which is hereby incorporated in its entirety by reference.
The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an a~ olul iate library containing the complete gene for a 30 RAT polynucleotide sequence under stringent hybridization conditions with a probe having the sequence of said RAT polynucleotide or a fragment thereof; and isolating said DNA sequence.

- ' CA 02222984 1998-02-06 Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein.
As discussed additionally herein regarding polynucleotide assays of the invention, for instance, polynucleotides of the invention as discussed above, may be used as a hybridization S probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding RAT and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the RAT gene. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred probes will have at least 30 bases and will have 50 bases or less.
For example, the coding region of the RAT gene may be isolated by screening using the known DNA sequence to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.
The polynucleotides and polypeptides of the invention may be employed as research reagents and materials for discovery of tre~tment~ of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays, inter alia.
Polynucleotides of the invention that are oligonucleotides derived from the RAT
polynucleotide sequences may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identif1ed herein in whole or in part are transcribed in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.
The polynucleotides may encode a polypeptide which is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes.
A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such - ~ CA 02222984 1998-02-06 inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.
In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein 5 having one or more prosequences which are not the leader sequences of a preprotein, or a plel)lol)lotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.
Vectors, host cells, expression The invention also relates to vectors which comprise a polynucleotide or polynucleotides of the invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA
constructs of the invention.
For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., BASICMETHODSINMOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECUL~R CLONING. ~ L~BOR~TORY M~NUAL, 2nd Ed., Cold 20 Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.
Representative examples of appropriate hosts include bacterial cells, such as streptococci, 25 staphylococci, E. coli, streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and ~spergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.
A great variety of expression systems can be used to produce a polypeptide of the invention. Such vectors include, among others, chromosomal, episomal and virus-derived 30 vectors, e.g, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
The expression system constructs may contain control regions that regulate as well as engender S expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORYMANUAL, (supra).
For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular ~l~vilolllllent, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
Polypeptides of the invention can be recovered and purified from recombinant cell 15 cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatitechromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may 20 be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
Diagnostic Assays This invention is also related to the use of the RAT polynucleotides of the invention for use as diagnostic reagents. Detection of RAT in a eukaryote, particularly a m~mm~l, and 25 especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly m~mm~l~, and especially humans, infected with an organism comprising the RAT gene may be detected at the DNA level by a variety of techniques.
Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for 30 detection or may be amplified enzymatically by using PCR or other amplification technique prior to analysis. RNA or cDNA may also be used in the same ways. Using amplification, characterization of the strain of prokaryote present in a eukaryote, particularly a m:~mm~l, and especially a human, may be made by an analysis of the genotype of the prokaryote gene.
Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing amplified DNA to labeled RAT polynucleotide sequences. Perfectly matched sequences can be distinguished from mi~m~tched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g, Myers et al., Science, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., Proc. Natl. Acad. Sci., USA, 85. 4397-4401 (1985).
Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA or cDNA
may also be used for the same purpose, PCR or RT-PCR. As an example, PCR primerscomplementary to the nucleic acid encoding RAT can be used to identify and analyze mutations.
These primers may also be used for amplifying RAT DNA isolated from a sample derived from an individual. The invention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to various techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence may be detected and used to diagnose infection and to serotype or classify the infectious agent.
The invention provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections by Stapllylococcus aureus, and most preferably disease, such as, infections of the upper respiratory tract (e.g., otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retroperitoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and perinephric absces, toxic shock syndrome), skin (e.g., impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis) bone and joint (e.g., septic arthritis, osteomyelitis), comprising determining from a sample derived from an individual a increased level of expression of RAT polynucleotide. Increased or decreased expression of RAT polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.
In addition, a diagnostic assay in accordance with the invention for detecting over-expression of RAT protein compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a RAT protein, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
Antibodies The polypeptides of the invention or variants thereof, or cells expressing them can be used as an immunogen to produce antibodies immunospecific for such polypeptides."Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeric, single chain, simi~ni7ed antibodies and humanized antibodies, as well as Fab fr~gment~, including the products of an Fab immunolglobulin expression library.
Antibodies generated against the polypeptides of the invention can be obtained by ~tlmini~tt~ring the polypeptides or epitope-bearing fragments, analogues or cells to an animal, preferably a nonhum:~n, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art which provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., Nature 256. 495-497 (1975); Kozbor et al., I~1l7nu~0logy Today 4: 72 (1983); Cole et al., pg. 77-96 in MONOCLON~L ANTIBODIES~ND C~NCER THER~PY, Alan R. Liss, Inc. (1985).
Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other m~mm~l.c, may be used to express hum~ni7.~d antibodies.
Alternatively phage display technology could be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of Iymphocytes from humans screened for possessing anti-polypeptide or from naive libraries (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).
If two antigen binding domains are present each domain may be directed against adifferent epitope - termed 'bispecific' antibodies.
The above-described antibodies may be employed to isolate or to identify clones e,~les~i,lg the polypeptides to purify the polypeptides by affinity chromatography.
Thus, among others, antibodies against RAT may be employed to treat infections, particularly bacterial infections and especially disease, such as, infections of the upper respiratory tract (e.g., otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retroperitoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and perinephric absces, toxic shock syndrome), skin (e.g., impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis) bone and joint (e.g., septic arthritis, osteomyelitis).
Polypeptide variants include antigenically, epitopically or immunologically equivalent variants which form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognised by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and m~mm~ n host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and m~mm~ n host.
The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively a multiple - ~ CA 02222984 1998-02-06 , .

antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be suff1ciently antigenic to improve immunogenicity so as to obviate the use of a carrier.
Preferably the antibody or variant thereof is modified to make it less immunogenic in 5 the individual. For example, if the individual is human the antibody may most preferably be "hl~m~ni7ed"; where the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al.,(1991) Biotechnology 9, 266-273.
The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992, 1 :363, Manthorpe et al., Hum. Gene Ther. 1963 :4, 419), delivery of DNA complexed with specific protein carriers (Wu et al., J Biol Chem1989:264,16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, PNAS, 1986:83,9551), encapsulation of DNA in various forms of liposomes (Kaneda et al., Science 1989:243,375), particle bombardment (Tang et al., Nature 1992, 356:152, Eisenbraun et al., DNA Cell Biol 1993, 12:791) and in vivo infection using cloned retroviral vectors (Seeger et al., PNAS 1984:81,5849).
Polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free ~ Lions, chemical libraries, and natural product nli~l~es. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan et al., Current Protocols in Immunology l f2):
Chapter 5 (1991).
Antagonists and agonists - assays and molecules The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of RAT polypeptides or polynucleotides.
For example, to screen for agonists or antagoists, a synthetic reaction mix, a cellular colllpalllllent, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising RAT polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule which may be a RAT agonist or antagonist.
The ability of the candidate molecule to agonize or antagonize the RAT polypeptide is reflected in ~ CA 02222984 1998-02-06 decreased binding of the labeled ligand or decreased production of product from such substrate.
Molecules which bind gratuitously, i. e., without inducing the effects of RAT are most likely to be good antagonists. Molecules that bind well and increase the rate of product production from substrate are agonists. The rate or level of production of product from substrate may be enhanced 5 by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in RAT activity, and binding assays known in the art.
Another example of an assay for RAT antagonists is a competitive assay that combines RAT and a potential antagonist with RAT-binding molecules, recombinant RAT binding 10 molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. RAT can be labeled, such as by radioactivity or a colorimetric compound, such that the number of RAT molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.
Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polypeptide of the invention and thereby inhibit or extinguish its activity.
Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing RAT-induced activities, thereby preventing the action of RAT by excluding RAT from binding.
Potential antagonists include a small molecule which binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, J. Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES
AS ANTISENSE INHIBITORS OF GENE E~'RESSION, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of RAT.
In a particular aspect the invention provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and m:~mm~ n host responsible for sequelae of infection. In particular the molecules of the invention may be used: i) in the prevention of adhesion of bacteria, in particular gram positive bacteria, to m~mm~ n extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; ii) to block RAT protein mediated m~mm~ n cell invasion by, for example, initiating phosphorylation of m~mm~ n tyrosine kinases (Rosenshine et al., Infect.
Immun. 60:2211 (1992); iii) to block bacterial adhesion between m~mm~ n extracellular matrix proteins and bacterial RAT proteins which mediate tissue damage; iv) to block the norrnal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.
Each of the DNA sequences provided herein may be used in the discovery and 10 development of antibacterial compounds. The encoded protein upon expression can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
The antagonists and agonists may be employed for instance to inhibit disease, such as, infections of the upper respiratory tract (e.g., otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retroperitoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and perinephric absces, toxic shock syndrome), skin (e.g., impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis) bone and joint (e.g., septic arthritis, osteomyelitis).
Vaccines Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a m~mm~l which comprises inoculating the individual with RAT, or a fragment or variant thereof, adequate to produce antibody to protect said individual from infection, particularly bacterial infection and most particularly Staphylococcus aureus infections. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises, through gene therapy, delivering gene encoding RAT, or a fragment or a variant thereof, for expressing RAT, or a fragment or a variant thereof i7l vivo in order to induce an immunological response to produce antibody to protect said individual from disease.
A further aspect of the invention relates to an immunological composition which, when introduced into a host capable or having induced within it an immunological response, induces an immunological response in such host to a RAT or protein coded therefrom, wherein the composition comprises a recombinant RAT or protein coded therefrom comprising DNA which codes for and expresses an antigen of said RAT or protein coded therefrom.
The RAT or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein 10 which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilise the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be 15 attached to either the amino or carboxy terminus of the first protein.
Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273:
352 (1996).
Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with Staphylococcus aureus will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune 25 response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Stap11ylococcus aureus infections, in m~mm~
particularly humans.
The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused e.g. by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth" "~ " " "~, y glands, urethra or vagina.
The invention also includes a vaccine formulation which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered palelltel~lly, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation instonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
While the invention has been described with reference to certain RAT, it is to be understood that this covers fragments of the naturally occurring protein and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.
Compositions, kits and administration The invention also relates to compositions comprising the polynucleotide or the polypeptides discussed above or the agonists or antagonists. The polypeptides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or org;~ni~m.c, such as a pharmaceutical carrier suitable for administration to a subject.
Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of ~(lmini~tration. The invention further relates to diagnostic and phammaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
Polypeptides and other compounds of the invention may be employed alone or in S conjunction with other compounds, such as therapeutic compounds.
The pharmaceutical compositions may be administered in any effective, convenientmanner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intrademmal routes among others.
In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.
Altematively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain a~ o~liate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
For administration to m~mm~ 7 and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters, etc.

.

The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device.
Treatment may be continued after surgery during the in-body time of the device. In addition, the composition could also be used to broaden perioperative cover for any surgical technique to 5 prevent bacterial wound infections, especially Staphylococcus aureus wound infections.
Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia.
Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to 10 extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.
In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an altemative to, or in conjunction with, antibiotic prophylaxis.
Altematively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of 1 llg/ml to 1 Omg/ml for bathing of wounds or indwelling devices.
A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-20 5~g/kg of antigen, and such dose is preferably ~-lmini~tered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.
The antibodies described above may also be used as diagnostic reagents to detect the 25 presence of bacteria containing the RAT protein.
EXAMPLES
The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.
30 Example 1 Library Production .

Each RAT polynucleotide having a DNA sequence that encodes a RAT polypeptide is obtained from a library of clones of chromosomal DNA of Staphylococcus aureus in E. coli. In some cases the sequencing data from two or more clones containing overlapping Staphylococcus aureus DNAs is used to construct the contiguous DNA sequence. Libraries 5 may be prepared by routine methods, for example:
Methods 1 and 2 below.
Total cellular DNA is isolated from Staphylococcus aureus WCUH 29 according to standard procedures and size-fractionated by either of two methods.
Method 1 Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures. DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added.
Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library. The library is amplified by standard procedures.
Method 2 Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes a~ op,iate to generate a series of fragments for cloning into library vectors (e.g., RsaI, PalI, AluI, Bshl235I), and such fragments are size-fractionated according to standard procedures. EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library. The library is amplified by standard procedures.
Example 2 RAT Characterization RAT enzymatic activity assay.
Radiolabelled 14C-glutamate is used to monitor conversion of (14C-Glu)-tRNAGln to (14C-Gln)-tRNAGln. (14C-Glx)-tRNAGln is deacylated and the products separated on a small (2 x 0.5 cm) Dowexl (chloride form) column; >95% glutamine is washed through and >99%
glutamate is retained.

Biological l~aterials for RAT work Analysis 1) Glu-tRNAGln.
2) Staphylococcal Glutamyl-tRNA Synthetase (herein also "ERS") for making Glu-tRNAGln.
See Figures 3 and 4 for ERS gene and protein sequences.
3) Substantially purified tRNA-dependent Amidotransferase from S.aureus.
RAT Analysis 1) Overexpression and purification of ERS.
The entire coding sequence of ERS was isolated. See Figures 3 and 4 for ERS gene and protein sequences. This sequence is cloned into a suitable expression vector to purify the protein in order to generate the Glu-tRNAGln used as a substrate in the RAT reaction.
2) Obtaining a suitable species of tRNAGln The S.aureus tRNAGln gene is constructed from synthetic oligonucleotides, overexpressed and purified and/or obtain E.coli tRNAGln- 1/2. tRNAGln so obtained could be tested for efficiency of misacylation with S.aureus ERS.
3) Purify S.aureus RAT
RAT is purified using (14C-Glu)-tRNAGln to track purification. Protein is assayed by deacylation and separation of glutamate from ~lu~ hle on Dowexl columns as described above.
4) Amino acid sequence determination N-terminal sequence and N-terminal sequences of proteolytically-derived internalpeptide fragments is derived using standard methods. These sequences are used to prepare probes to isolate the full length RAT gene from a S.aureus WCUH29 phage library.5) Overexpress and purify RAT
After cloning and sequencing, the RAT protein is overexpressed and purified for biochemical/ enzymological/ structural studies and to provide material for compound screemng.
6) Compound Screening High Throughput Screening. High-throughput compound screens are set up without recourse to use of radiolabelled glutamate and ion-exchange chromatography. The amidotransferase reaction utilises ATP to form a transient y-phosphoryl intermediate.

i Theenzyme activity is assessed by photometric determination of Pi release from ATP. [A
colourimetric assay for Pi [5]. This assay is expected to detect Pi levels with nM sensitivity].
Natural Product Screens. Natural Product screen assays of RAT activity may be performed by the separation of 14C-glutamate from 14C-glutamine. Elution from ion-exchange S columns may be used to separate 14C-glutamate from 14C-glutamine by batch absorption onto Dowexl using known methods.

7) Controls Glutamine Synthase (for example) could serve as a control for the specificity of any compounds testing positive. The enzyme is commercially available. If necessary, the protein 10 could probably be prepared as the enzyme is extremely well-characterised (i.e. purification, biochemistry, crystal structure).
There are a number of glutamine analogues (azaserine, methionine sulphoximine and 6-diazo-5-oxo-L-norleucine) that are known inhibitors of amidotransferases. It is provided by the invention that these will inhibit RAT. These compounds are commercially available and are 15 tested as set forth above, as well as in any known assays. They also serve as positive control for test compounds in in vitro assays. Positive compounds could also be tested in a whole cell assay; E.coli possesses a GlnRS and should therefore be unaffected by a RAT-specific inhibitor whereas R.meliloti (also a Gram-negative with presumably similar permeability barriers) does not possess GlnRS and therefore relies on RAT and would be expected to be susceptible.
20 Example 3 RAT assay (Glu-tRNAgln amidotranferase) The assay used is that of Zalkin (Methods in Enzymology (1985) 113, 303-305) The reaction is as follows:
Glu-tRNAGIn +ATP +glutamine Gln-tRNAGIn+ATP+Pi +glutamate The assay is as follows 25 Final reaction mixture is 50ul, The following reagents are added(Sul of each) Potassium cacodylate(500mM), 2-mercaptoethanol(SOmM), MgC12(5mM), (14C) S.aureusGlu-tRNAgln(prepared by ERS charging of purified S.aureus tRNA), ATP (lOOmM) . Water and enzyme are then added to a final volume of SOul. The assay is incubated at 30C for S
30 minutes. The reaction is stopped by addition of O.Sml of KOH (0.02M), incubated for a further ~minutes and neutralized by the addition of O.lml HCI (O.lM). Samples are applied to a , CA 02222984 1998-02-06 .

column of Dowexl (Cl- form),0.5x2cm, equilibrated with water. The column is washed with 1.5ml of water and the eluted material collected and counted in a Wallac Microbetaplate counter. Cell lysates of S.aureus Oxford have a specific activity of between about 0.1 -0.3nmoles/min/mg. Highly purified preparations have a specific activity of about5 25nmoles/min/mg. Material of this purity was run on native SDS polyacrylamide electrophoresis gels and shows a principal species consistent with a molecular weight 11 OkD.
Electrophoresis on reducing SDS Page show two species of approx. 54 and 55kD. This suggests that one embodiment of the invention is a molecule which exists as a heterodimer.
Examination of substantially purified material may be carried out using by N-terminal 10 analysis (twice) methods known in the art. N-temminally blocked proteinis digested with trypsin and intemal sequence is perfommed. A method for mass determination is MALDI MS.
References 1) Wilcox, M., Eur. J. Biochem. 11, 405-412, 1969 2) Jahn, D., et al, J. Biol. Chem. 265, 8059-8064, 1990 3) Strauch, M.A., et al, J. Bacteriol 170, 916-920, 1988 4) Lamour, V., et al, Proc. Natl. Acad. Sci. 91, 8670-8674, 1994 5) Lanzetta, P.A. et al, Anal. Biochem. 100, 95-97, 1979 SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: Black, Michael T.
Lewis, Cerl J.
(ii) TITLE OF THE INVENTION: Novel RAT

(iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Dechert, Price & Rhoads (B) STREET: 4000 Bell Atlantic Tower, 1717 Arch Stre (C) CITY: Philadelphia (D) STATE: PA
(E) COUNTRY: USA
(F) ZIP: 19103-2793 ~v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette (B) COM~Ul~:~: IBM Compatible (C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 60/037,857 (B) FILING DATE: 07-FEB-1997 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Falk, Stephen T
(B) REGISTRATION NUMBER: 36,795 (C) REFERENCE/DOCKET NUMBER: GM50012 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 215-994-2488 (B) TELEFAX: 215-994-2222 (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1458 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear CA 02222984 l998-02-06 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
ATGAGCGATC GTAT~AGAGT ~AGATATGCA CCAAGTCCAA CTGGTTATCT TCATATTGGT 60 (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 484 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Ser Asp Arg Ile Arg Val Arg Tyr Ala Pro Ser Pro Thr Gly Tyr Leu His Ile Gly Asn Ala Arg Thr Ala Leu Phe Asn Tyr Leu Tyr Ala Lys His Tyr Asn Gly Asp Phe Val Ile Arg Ile Glu Asp Thr Asp Lys Lys Arg Asn Leu Glu Asp Gly Glu Thr Ser Gln Phe Asp Asn Leu Lys Trp Leu Gly Leu Asp Trp Asp Glu Ser Val Asp Lys Asp Asn Gly Tyr Gly Pro Tyr Arg Gln Ser Glu Arg Gln His Ile Tyr Gln Pro Leu Ile Asp Gln Leu Leu Ala Glu Asp Lys Ala Tyr Lys Cys Tyr Met Thr Glu Glu Glu Leu Glu Ala Glu Arg Glu Ala Gln Ile Ala Arg Gly Glu Met Pro Arg Tyr Gly Gly Gln His Ala His Leu Thr Glu Glu Gln Arg Gln Gln Phe Glu Ala Glu Gly Arg Gln Pro Ser Ile Arg Phe Arg Val Pro Gln ~sn Gln Thr Tyr Ser Phe Asp Asp Met Val Lys Gly Asn Ile Ser Phe Asp Ser Asn Gly Ile Gly Asp Trp Val Ile Val Lys Lys Asp Gly Ile Pro Thr Tyr Asn Phe Ala Val Ala Ile Asp Asp His Tyr Met Gln Ile Ser Asp Val Ile Arg Gly Asp Asp His Ile Ser Asn Thr Pro Lys Gln Ile Met Ile Tyr Glu Ala Phe Gly Trp Glu Pro Pro Arg Phe Gly His Met Ser Leu Ile Val Asn Glu Glu Arg Lys Lys Leu Ser Lys Arg Asp Gly Gln Ile Leu Gln Phe Ile Glu Gln Tyr Arg Asp Leu Gly Tyr Leu Pro Glu Ala Leu Phe Asn Phe Ile Ala Leu Leu Gly Trp Ser Pro Glu Gly Glu Glu Glu Ile Phe Ser Lys Glu Glu Phe Ile Lys Ile Phe Asp Glu Lys Arg Leu Ser Lys Ser Pro Ala Phe Phe Asp Lys Gln Lys Leu Ala Trp Val Asn Asn Gln Tyr Met Lys Gln Lys Asp Thr Glu Thr Val Phe Gln Leu Ala Leu Pro His Leu Ile Lys Ala Asn Leu Ile Pro Glu Val Pro Ser Glu Glu Asp Leu Ser Trp Gly Arg Lys Leu Ile Ala Leu Tyr Gln Lys Glu Met Ser Tyr Ala Gly Glu Ile Val Pro Leu Ser Glu Met Phe Phe Lys Glu Met Pro Ala Leu Gly Glu Glu Glu Gln Gln Val Ile Asn Gly Glu Gln Val Pro Glu Leu Met Thr His Leu Phe Ser Lys Leu Glu Ala Leu Glu Pro Phe Glu Ala Ala Glu Ile Lys Lys Thr Ile Lys Glu Val Gln Lys Glu Thr Gly Ile Lys Gly Lys Gln Leu Phe Met Pro Ile Arg Val Ala Val Thr Gly Gln Met His Gly Pro Glu Leu Pro Asn Thr Ile Glu Val Leu Gly Lys Glu Lys Val Leu Asn Arg Leu Lys Gln Tyr Lys

Claims (30)

1. An isolated polynucleotide comprising a polynucleotide sequence selected fromthe group consisting of:
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising amino acids sequence determined by sequencing the RAT protein;
(b) a polynucleotide which is complementary to the polynucleotide of (a); and (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).

2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.

3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.

4. The polynucleotide of Claim 2 comprising the RAT gene that encodes the RAT
polypeptide having the amino acid sequence determined by sequencing the RAT protein.

5. The polynucleotide of Claim 2 comprising RAT polynucleotide.

6. The polynucleotide of Claim 2 which encodes a polypeptide comprising the amino acid sequence determined by sequencing the RAT protein.

7. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the RAT gene contained in NCIMB Deposit No. 40771;
(b) a polynucleotide complementary to the polynucleotide of (a); and (c) a polynucleotide comprising at least 15 bases of the polynucleotide of (a) or (b).

8. A vector comprising the DNA of Claim 2.

9. A host cell comprising the vector of Claim 8.

10. A process for producing a polypeptide comprising: expressing from the host cell of Claim 9 a polypeptide encoded by said DNA.

11. A process for producing a cell which expresses a polypeptide comprising transforming or transfecting the cell with the vector of Claim 8 such that the cell expresses the polypeptide encoded by the cDNA contained in the vector.

12. A process for producing a RAT polypeptide or fragment comprising culturing ahost of claim 9 under conditions sufficient for the production of said polypeptide or fragment.

13. A polypeptide comprising an amino acid sequence which is at least 70% identical to the RAT polypeptide having the amino acid sequence determined by sequencing the RAT
protein.

14. A polypeptide comprising an amino acid sequence which encodes the RAT
polypeptide having the amino acid sequence determined by sequencing the RAT protein.

15. An antibody against the polypeptide of claim 13.

16. An antagonist which inhibits the activity of the polypeptide of claim 13.

17. A method for the treatment of an individual having need of RAT comprising:
administering to the individual a therapeutically effective amount of the polypeptide of claim 13.

18. The method of Claim 17 wherein said therapeutically effective amount of the polypeptide is administered by providing to the individual DNA encoding said polypeptide and expressing said polypeptide in vivo.

19. A method for the treatment of an individual having need to inhibit RAT
polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of Claim 16.

20. A process for diagnosing a disease related to expression of the polypeptide of claim 13 comprising:
determining a nucleic acid sequence encoding said polypeptide.

21. A diagnostic process comprising:
analyzing for the presence of the polypeptide of claim 13 in a sample derived from a host.

22. A method for identifying compounds which bind to and inhibit an activity of the polypeptide of claim 13 comprising:
contacting a cell expressing on the surface thereof a binding for the polypeptide, said binding being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said binding, with a compound to be screened under conditions to permit binding to the binding; and determining whether the compound binds to and activates or inhibits the binding by detecting the presence or absence of a signal generated from the interaction of the compound with the binding.

23. A method for inducing an immunological response in a mammal which comprises inoculating the mammal with RAT, or a fragment or variant thereof, adequate to produce antibody to protect said animal from disease.

24. A method of inducing immunological response in a mammal which comprises, through gene therapy, delivering gene encoding RAT fragment or a variant thereof, for expressing RAT, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody to protect said animal from disease.

25. An immunological composition comprising a DNA which codes for and expresses a RAT polynucleotide or protein coded therefrom which, when introduced into a mammal, induces an immunological response in the mammal to a given RAT polynucleotide or protein coded therefrom.

26. A polynucleotide consisting essentially of a DNA sequence obtainable by screening an appropriate library containing the complete gene for a RAT polynucleotide sequence under stringent hybridization conditions with a probe having the sequence of said RAT polynucleotide sequence or a fragment thereof; and isolating said DNA sequence.

27. The use of a therapeutically effective amount of the polypeptide of claim 13 to treat an individual having need of RAT.

28. The use of a therapeutically effective amount of the antagonist of claim 16 to treat an individual having need to inhibit RAT polypeptide.

29. The use of RAT, or a fragment or variant thereof, to induce an immunologicalresponse in a mammal.

30. The use of a gene encoding RAT fragment or a variant thereof, for expressingRAT, or a fragment or a variant thereof in vivo to induce an immunological response in a mammal.